

[Brazil's Embraer returns to China with deal for freight conversions | Reuters | June 21, 2023](#)

Brazilian planemaker **Embraer** is returning to China with a deal to convert passenger jets into freight aircraft with a local partner in the northwestern city of Lanzhou, the company said on June 21.

Anticipation of new business in China has been high since President Luiz Inacio Lula da Silva's trip to China in April (see [TCS April 7](#)). At the time, he publicly backed Embraer's efforts to return to a market where it has struggled to find new business since the 2016 closure of a joint venture in Harbin.

Some had expected a deal for aircraft sales to a Chinese airline. Instead, Embraer announced ...that it had signed a letter of agreement with Lanzhou Aviation Industry Development Group for 20 E190F and E195F **passenger-to-freighter conversions**.

...Financial details of this deal were not disclosed. Embraer said in a statement that the companies intend to cooperate on establishing conversion capability in Lanzhou to boost the introduction of first-generation E-Jet freighters to the Chinese market.

Embraer forecasts demand for such jets to reach 700 aircraft over the next 20 years, with China responsible for 240 of them, and said the deal with Lanzhou was a "strong indicator" of such demand.

The Brazilian firm, the world's third-largest planemaker, currently has 85 E-Jets flying in China with carriers Tianjin, Hebei, Beibu Gulf and Colorful Guizhou.

[China aprueba uso de medicamento cubano para cáncer de páncreas | Crónica Digital | June 12, 2023](#)

~ These quotes have been paraphrased from Spanish ~

China's National Medical Products Administration (NMPA) approved the marketing and use of Cuba's humanized monoclonal antibody Nimotuzumab for the **treatment of pancreatic cancer**.

The decision follows a series of investigations carried out by the two countries' joint venture Biotech Pharma (BPL) on expanding the application of the drug here beyond the therapy against nasopharyngeal cancer.

Prior to that, Cuban-Chinese biotechnological collaboration had notably produced the launch of "Pan-Corona" COVID-19 vaccine in June 2022 (see [TCS June 6](#)). (RP)